3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
53
Prostate Cancer Metastatic
6
Neoplasm Metastasis
6
Carcinoma, Transitional Cell
4
Neoplastic Cells, Circulating
3
Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Urinary Bladder Neoplasms
2
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Thrombocytosis
1
Testicular Neoplasms
1
Prostate Cancer, Hereditary, 7
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
Blood Specimen Collection
8
cabazitaxel
3
Reverse Transcriptase Polymerase Chain Reaction
2
Flow Cytometry
2
Anesthesia, General
2
Leukapheresis
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Docetaxel
1
Data Collection
1
Antiemetics
1
Anesthesia, Spinal
1
Analgesia, Epidural
1
Adrenal Cortex Hormones
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplastic Cells, Circulating
×
cabazitaxel
×
Genitourinary
×
Clear all
NCT03101046
2022-02-10
TACTIK
UNICANCER
Phase 2
Completed
40 enrolled
NCT03050866
2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2
Unknown
140 enrolled
NCT02621190
2016-08-17
CARVE
Erasmus Medical Center
Phase 2
Withdrawn